Sarah B Goldberg Selected Research

Sarah B Goldberg Research Topics

Disease

33	Neoplasms (Cancer) 10/2023 - 12/2014
30	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 10/2012
15	Brain Neoplasms (Brain Tumor) 10/2023 - 04/2013
14	Lung Neoplasms (Lung Cancer) 10/2023 - 09/2015
9	Melanoma (Melanoma, Malignant) 09/2021 - 12/2014
8	Neoplasm Metastasis (Metastasis) 11/2021 - 09/2015
3	Disease Progression 10/2023 - 12/2019
3	Adenocarcinoma of Lung 01/2020 - 01/2016
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 04/2013
2	Edema (Dropsy) 01/2019 - 01/2019
2	Colitis 07/2016 - 03/2016
1	Neurologic Manifestations (Neurological Manifestations) 01/2023
1	Mesothelioma 01/2022
1	Multiple Sclerosis 06/2021
1	Diarrhea 12/2020
1	Exanthema (Rash) 12/2020
1	Epilepsy (Aura) 01/2020
1	Ovarian Neoplasms (Ovarian Cancer) 01/2020
1	Central Nervous System Diseases (CNS Diseases) 01/2020
1	Hemorrhage 12/2019
1	Necrosis 12/2019
1	Seizures (Absence Seizure) 01/2019
1	Bullous Pemphigoid (Pemphigoid) 12/2018
1	Dermatitis 12/2018
1	Linear IgA Bullous Dermatosis 12/2018
1	Inflammation (Inflammations) 01/2018
1	Fatigue 07/2016
1	Pneumonia (Pneumonitis) 07/2016
1	Hyperkalemia 07/2016
1	Acute Kidney Injury (Acute Renal Failure) 07/2016
1	Pericardial Effusion 03/2016
1	Myasthenia Gravis 03/2016
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2016
1	Adenocarcinoma 01/2016
1	Colonic Neoplasms (Colon Cancer) 01/2016

Drug/Important Bio-Agent (IBA)

12	Tyrosine Kinase InhibitorsIBA 10/2023 - 01/2013
11	Immune Checkpoint InhibitorsIBA 01/2023 - 03/2016
7	ErbB Receptors (EGF Receptor)IBA 01/2023 - 01/2013
7	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 10/2012
7	pembrolizumabIBA 01/2020 - 03/2016
6	osimertinibIBA 01/2024 - 01/2020
6	Biomarkers (Surrogate Marker)IBA 12/2023 - 10/2016
4	durvalumabIBA 01/2024 - 03/2016
4	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023 - 07/2016
4	AfatinibIBA 01/2022 - 01/2016
3	tremelimumabIBA 01/2023 - 03/2016
3	Cetuximab (Erbitux)FDA Link 01/2022 - 01/2016
2	GenieIBA 10/2023 - 01/2023
2	B7-H1 AntigenIBA 10/2021 - 01/2019
2	LigandsIBA 06/2021 - 01/2020
2	Phosphotransferases (Kinase)IBA 01/2021 - 01/2018
2	AntibodiesIBA 01/2020 - 12/2017
1	Programmed Cell Death 1 ReceptorIBA 01/2023
1	Anaplastic Lymphoma KinaseIBA 01/2023
1	Prednisone (Sone)FDA LinkGeneric 01/2023
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2022
1	palbociclibIBA 07/2022
1	Granzymes (Granzyme)IBA 10/2021
1	cyclo(Arg-Pro) (CI 4)IBA 09/2021
1	atezolizumabIBA 06/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	Cell-Free Nucleic AcidsIBA 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2020
1	CTLA-4 AntigenIBA 01/2020
1	lifastuzumab vedotinIBA 01/2020
1	PlatinumIBA 01/2020
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2019
1	Vancomycin FDA LinkGeneric 12/2018
1	Circulating Tumor DNAIBA 01/2018
1	Histocompatibility Antigens Class IIBA 12/2017
1	InterferonsIBA 12/2017
1	AZD 6244IBA 10/2016
1	Sorafenib (BAY 43-9006)FDA Link 10/2016
1	MK 2206IBA 10/2016
1	Transaminases (Aminotransferases)IBA 07/2016
1	Immunomodulating AgentsIBA 03/2016
1	Lipase (Acid Lipase)FDA Link 03/2016
1	Monoclonal AntibodiesIBA 12/2014
1	Platinum Compounds (Compounds, Platinum)IBA 04/2013
1	Cisplatin (Platino)FDA LinkGeneric 04/2013
1	Etoposide (VP 16)FDA LinkGeneric 04/2013
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 10/2012

Therapy/Procedure

30	Therapeutics 12/2023 - 01/2015
17	Immunotherapy 01/2023 - 12/2014
10	Drug Therapy (Chemotherapy) 01/2023 - 01/2013
7	Radiotherapy 01/2023 - 04/2013
6	Precision Medicine 01/2022 - 01/2018
1	Craniotomy 01/2021
1	Adjuvant Chemotherapy 11/2020
1	Duration of Therapy 01/2020
1	Intravenous Infusions 01/2020
1	Lasers (Laser) 12/2019
1	Cranial Irradiation 04/2013